Denosumab for treating osteoporosis and glucocorticoid-associated bone loss

Published on 03 May 2017
Last Updated on 01 Jul 2022

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Denosumab 60 mg/mL prefilled syringe for treating patients with osteoporosis (T-score ≤ -2.5) at high risk of fracture.

Patients must also receive adequate calcium and vitamin D supplementation whilst undergoing treatment.

Subsidy status

Denosumab 60 mg/mL prefilled syringe is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 July 2022.

MAF assistance does not apply to denosumab 60 mg/mL prefilled syringe when used for treating glucocorticoid-associated bone loss.

Denosumab for treating osteoporosis and glucocorticoid-associated bone loss (Updated 1 July 22) [PDF, 148 KB]

PES Denosumab for treating osteoporosis (Published 1 July 2022) [PDF, 118 KB]